Search Results 511-520 of 18342 for alopecia

  1. VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer - Mayo Clinic

    4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgment are ...

  2. Publications - Olayemi Sokumbi, M.D. - Mayo Clinic

    Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid. J Drugs Dermatol. 2022 Aug 1; 21 (8):894-895. View PubMed; Smith SDB, Okoye GA ...

  3. Bleomycin (injection route) - Mayo Clinic

    Bleomycin belongs to the general group of medicines called antineoplastics. It is used to treat several types of cancer, including cervix and uterus cancer, ...

  4. Dacarbazine (intravenous route, injection route) - Side effects & dosage - Mayo Clinic

    Dacarbazine belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin ...

  5. Melanoma - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Nonmelanoma skin cancer, Tuberous sclerosis ...

  6. Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors - Mayo Clinic

    ... alopecia) and/or in whom ≥ 25% of the bone marrow was irradiated. Major surgery ≤ 14 days prior to registration or has not recovered from major side ...

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  8. A Study Of Radiation Dosimetry, Safety, And Tolerability Of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment In Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer

    * Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies except alopecia. Key exclusion ...

  9. Study to Investigate the Safety and Effectiveness of Two Doses of the Antibody Drug GSK2857916 in Relapsed/Refractory Multiple Myeloma Patients - Mayo Clinic

    ... alopecia and Grade 2 peripheral neuropathy. For France only: A subject will be eligible for inclusion in this study only if either affiliated to or a ...

  10. Clinical trials - Oncology (Medical)

    Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...